Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

2.

Is there a delay in the antidepressant effect? A meta-analysis.

Posternak MA, Zimmerman M.

J Clin Psychiatry. 2005 Feb;66(2):148-58.

PMID:
15704999
3.

Factors that influence the outcome of placebo-controlled antidepressant clinical trials.

Niklson IA, Reimitz PE, Sennef C.

Psychopharmacol Bull. 1997;33(1):41-51.

PMID:
9133750
4.

Placebo response and antidepressant clinical trial outcome.

Khan A, Detke M, Khan SR, Mallinckrodt C.

J Nerv Ment Dis. 2003 Apr;191(4):211-8.

PMID:
12695731
5.

Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.

Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, Lanctôt KL.

J Clin Psychiatry. 2010 Mar;71(3):270-9. doi: 10.4088/JCP.08r04516blu. Epub 2010 Jan 26. Review.

PMID:
20122371
6.

Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

Papakostas GI, Fava M.

Eur Neuropsychopharmacol. 2009 Jan;19(1):34-40. doi: 10.1016/j.euroneuro.2008.08.009. Epub 2008 Sep 26. Review.

PMID:
18823760
7.

Meta-analysis of placebo rates in major depressive disorder trials.

Stolk P, Ten Berg MJ, Hemels ME, Einarson TR.

Ann Pharmacother. 2003 Dec;37(12):1891-9.

PMID:
14632596
8.

A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder.

Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M.

J Clin Psychopharmacol. 2006 Feb;26(1):56-60.

PMID:
16415707
9.

A randomized controlled trial of sertraline for the treatment of depression in persons with traumatic brain injury.

Ashman TA, Cantor JB, Gordon WA, Spielman L, Flanagan S, Ginsberg A, Engmann C, Egan M, Ambrose F, Greenwald B.

Arch Phys Med Rehabil. 2009 May;90(5):733-40. doi: 10.1016/j.apmr.2008.11.005.

PMID:
19406291
10.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
11.

Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.

Shelton RC, Prakash A, Mallinckrodt CH, Wohlreich MM, Raskin J, Robinson MJ, Detke MJ.

Int J Clin Pract. 2007 Aug;61(8):1337-48. Review.

PMID:
17627710
12.

Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants.

Mukai Y, Tampi RR.

Clin Ther. 2009 May;31(5):945-61. doi: 10.1016/j.clinthera.2009.05.016. Review.

PMID:
19539096
14.

The mousetrap: managing the placebo effect in antidepressant trials.

Lakoff A.

Mol Interv. 2002 Apr;2(2):72-6. Review. No abstract available.

PMID:
14993352
15.

Risperidone for treatment-refractory major depressive disorder: a randomized trial.

Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, Gharabawi-Garibaldi GM.

Ann Intern Med. 2007 Nov 6;147(9):593-602.

PMID:
17975181
16.

Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database.

Khan A, Leventhal RM, Khan SR, Brown WA.

J Clin Psychopharmacol. 2002 Feb;22(1):40-5.

PMID:
11799341
17.

A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.

Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.

J Psychiatr Res. 2008 Jan;42(1):22-34. Epub 2007 Apr 18.

PMID:
17445831
18.

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.

Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA.

Int Clin Psychopharmacol. 2007 Nov;22(6):338-47.

PMID:
17917552
19.

The persistence of the placebo response in antidepressant clinical trials.

Khan A, Redding N, Brown WA.

J Psychiatr Res. 2008 Aug;42(10):791-6. Epub 2007 Nov 26. Review.

PMID:
18036616
20.

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW.

J Clin Psychopharmacol. 2008 Dec;28(6):631-7. doi: 10.1097/JCP.0b013e31818a6cea.

PMID:
19011431

Supplemental Content

Support Center